The Biosimilars Market is predicted to reach US$ ~87.12 billion by 2030 from US$ ~15.1 billion in 2021, and to grow at a CAGR of ~21.5% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Product (Recombinant Glycosylated Proteins, Recombinant Peptides and Recombinant Non-Glycosylated Proteins), Disease Indication (Infectious Diseases, Oncology, Autoimmune Diseases, Growth Hormone Deficiency and Blood Disorders) Manufacturing Type (In-House Manufacturing and Contract Manufacturing)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Pfizer Inc., Sandoz International GmbH, Amgen Inc., Samsung Biologics., Biocon, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Celltrion Healthcare Co.,Ltd., Mylan N.V., STADA Arzneimittel AG, among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Biosimilars Market - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Biosimilars Market - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Biosimilars Market - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Biosimilars Market - ANALYSIS & FORECAST, BY REGION
North America Biosimilars Market
1. North America Biosimilars Market, by Country
1. US
2. Canada
1. North America Biosimilars Market, by Product
2. North America Biosimilars Market, by Type
3. North America Biosimilars Market, by Gender
4. North America Biosimilars Market, by Sales Channel
3. Europe Biosimilars Market
1. Europe Biosimilars Market, by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Biosimilars Market, by Product
3. Europe Biosimilars Market, by Type
4. Europe Biosimilars Market, by Gender
5. Europe Biosimilars Market, by Sales Channel
4. Asia Pacific Biosimilars Market
1. Asia Pacific Biosimilars Market, by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Biosimilars Market, by product
3. Asia Pacific Biosimilars Market, by Type
4. Asia Pacific Biosimilars Market, by Gender
5. Asia Pacific Biosimilars Market, by Sales Channel
5. Rest of the World Biosimilars Market
1. Rest of the World Biosimilars Market, by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Biosimilars Market, by Product
3. Rest of the World Biosimilars Market, by Type
4. Rest of the World Biosimilars Market, by Gender
5. Rest of the World Biosimilars Market, by Sales Channel
2. COMPANY PROFILES
Company 1, Company 11
The Biologics and Biosimilars CXO Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landsca...
Executive Summary
Azoth Analytics has released a research report titled Global Therapeutics Market (2024 Edition) which provides a complete analysis of the Global Therapeutics industry in terms of market segmentation By Molecule Type (Biologics and Biosimilars, Small Molecules), By Th...
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology s...
Global bioprocess technology market will reach $88.39 billion by 2033, growing by 13.8% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing technologic...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...
Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing cl...